At a glance
- Originator Celgene Corporation
- Class Antiasthmatics; Phthalimides; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Aphthous stomatitis; Asthma; Cachexia; HIV-1 infections
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 13 Nov 2002 No development reported - Phase-I for Asthma (PO)
- 11 Nov 2002 No development reported - Preclinical for HIV-1 infections in Italy (unspecified route)